MDM2 and renal cell carcinoma: Furthermore, the application of the signature across a large set of human tumor samples revealed new indications of potential interest for the development of p53–HDM2 inhibitors, such as renal cell carcinoma and hepatocellular carcinoma (Figure 4C), that had been previously missed due to their under-representation in the set of CCLE cell lines tested.